Monica Phadnis is VP, Clinical Operations at Acrivon Therapeutics. Monica brings 17 plus years of global clinical oncology strategy and operations experience in biotech, pharma, clinical research organizations and academic settings. She is an end-to-end delivery expert for precision medicine treatments (TEPMETKO®, tepotinib), immunotherapy (BAVENCIO®, avelumab), and antibody-drug conjugate targeted therapies (ENHERTU®, fam-trastuzumab deruxtecan-nxki).
Monica began her career as a Program Manager in Selventa, a company discovering genetic pathways for drug resistant solid tumors. She was recruited by Memorial Sloan-Kettering to lead the Breast and Thoracic Oncology Unit as a Portfolio Manager where she managed the entire portfolio of 75 plus clinical trials and staff of 30 plus to deliver various institutional and sponsor based multi-phase studies. She was selected as the New York State leader for Cancer and Leukemia Group B (CALGB) national program. Monica then developed her career as Therapeutic Compound Lead and Executive Director for Iqvia and Syneos respectively where she was program management head of Tepotinib and Bavencio. In her recent roles as VP of Clinical Operations at Relay and MetaboMed, Monica filed two INDs and up started entire clinical operations department including multiple vendor selections across US, EU and Asia.
Monica is a frequent ASCO poster presenter as well as guest speaker and panelist for many oncology conferences. She holds a bachelor’s degree in Mathematics from University of Mumbai and Pre-Medicine Diploma from Harvard University.